# Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

> **NCT06484114** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Fractyl Health Inc.** · enrollment: 315 (estimated)

## Conditions studied

- Obesity
- Weight Change Trajectory
- Weight Change, Body

## Interventions

- **DEVICE:** Revita Duodenal Mucosal Resurfacing (DMR)
- **DEVICE:** Sham

## Key facts

- **NCT ID:** NCT06484114
- **Lead sponsor:** Fractyl Health Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-02-15
- **Final completion:** 2027-02-26
- **Target enrollment:** 315 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06484114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06484114, "Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06484114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*